A Van der Walt
Overview
Explore the profile of A Van der Walt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hardy T, Aouad P, Barnett M, Blum S, Broadley S, Carroll W, et al.
Mult Scler J Exp Transl Clin
. 2024 Jan;
10(1):20552173231226106.
PMID: 38222025
Background: Siponimod is approved for use in people with secondary progressive multiple sclerosis (pwSPMS). An integrated digital platform, MSGo, was developed for pwSPMS and clinicians to help navigate the multiple...
2.
Spelman T, Herring W, Acosta C, Hyde R, Jokubaitis V, Pucci E, et al.
J Med Econ
. 2023 Dec;
27(1):109-125.
PMID: 38085684
Aim: To evaluate the real-world comparative effectiveness and the cost-effectiveness, from a UK National Health Service perspective, of natalizumab versus fingolimod in patients with rapidly evolving severe relapsing-remitting multiple sclerosis...
3.
Lefort M, Sharmin S, Andersen J, Vukusic S, Casey R, Debouverie M, et al.
BMC Med Res Methodol
. 2022 May;
22(1):155.
PMID: 35637426
Background: Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment...
4.
Kolbe S, Garcia L, Yu N, Boonstra F, Clough M, Sinclair B, et al.
AJNR Am J Neuroradiol
. 2022 Feb;
43(2):238-244.
PMID: 35121585
Background And Purpose: Perivascular spaces surround the blood vessels of the brain and are involved in neuroimmune functions and clearance of metabolites via the glymphatic system of the brain. Enlarged...
5.
Noffs G, Boonstra F, Perera T, Butzkueven H, Kolbe S, Maldonado F, et al.
Eur J Neurol
. 2020 Sep;
28(1):259-268.
PMID: 32916031
Background And Purpose: Objective measurement of speech has shown promising results to monitor disease state in multiple sclerosis. In this study, we characterize the relationship between disease severity and speech...
6.
De Meijer L, Merlo D, Skibina O, Grobbee E, Gale J, Haartsen J, et al.
Mult Scler J Exp Transl Clin
. 2018 Dec;
4(4):2055217318815513.
PMID: 30559973
Background: Cognitive monitoring that can detect short-term change in multiple sclerosis is challenging. Computerized cognitive batteries such as the CogState Brief Battery can rapidly assess commonly affected cognitive domains. Objectives:...
7.
Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, et al.
Eur J Neurol
. 2018 Oct;
26(2):363-370.
PMID: 30298572
Background And Purpose: Treatment options in primary progressive multiple sclerosis (PPMS) are scarce and, with the exception of ocrelizumab, anti-inflammatory agents have failed to show efficacy in ameliorating disability progression....
8.
Van der Walt A, Buzzard K, Sung S, Spelman T, Kolbe S, Marriott M, et al.
Mult Scler
. 2015 May;
21(14):1847-55.
PMID: 26014602
Background: The pathophysiology of multiple sclerosis (MS) tremor is uncertain with limited phenotypical studies available. Objective: To investigate whether dystonia contributes to MS tremor and its severity. Methods: MS patients...
9.
Gresle M, Liu Y, Dagley L, Haartsen J, Pearson F, Purcell A, et al.
J Neurol Neurosurg Psychiatry
. 2014 Mar;
85(11):1209-13.
PMID: 24639436
Objectives: We evaluated whether the measurement of serum phosphorylated neurofilament heavy chain (pNF-H) titre is likely to be a valid biomarker of axonal injury in multiple sclerosis (MS). Methods: Serum...
10.
Klistorner A, Garrick R, Paine M, Graham S, Arvind H, Van der Walt A, et al.
J Neurol Neurosurg Psychiatry
. 2011 Dec;
83(3):311-4.
PMID: 22193562
Background: Axonal loss is a major determinant of disability in multiple sclerosis (MS). While acute inflammatory demyelination is a principal cause of axonal transection and subsequent axonal degeneration in acute...